African health sciences · 2024
Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qian Jiancheng, Sun Xiaoyong, Cheng Yue
Аннотация
BACKGROUND: To observe and analyse the clinical effects of entecavir on serum hyaluronic acid (HA), laminin (LN), and type IV collagen (IVC) in patients with hepatitis B e-antigen (HBeAG)-positive chronic hepatitis B during clinical treatment.
METHODOLOGY: The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy. The clinical curative effects of immune checkpoint inhibitors at different concentrations on diseases were compared from all aspects.
RESULTS: There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05). The levels of liver function indicators, immune function-related indicators (CD3+, CD4+, CD8+, CD4+/CD8+, CD4+/CD8+), and HA, LN and IVC were not statistically different between the two groups before treatment.
CONCLUSION: Entecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B. However, entecavir + thymalfasin combination therapy can alleviate the clinical symptoms. In this way, liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.
METHODOLOGY: The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy. The clinical curative effects of immune checkpoint inhibitors at different concentrations on diseases were compared from all aspects.
RESULTS: There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05). The levels of liver function indicators, immune function-related indicators (CD3+, CD4+, CD8+, CD4+/CD8+, CD4+/CD8+), and HA, LN and IVC were not statistically different between the two groups before treatment.
CONCLUSION: Entecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B. However, entecavir + thymalfasin combination therapy can alleviate the clinical symptoms. In this way, liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.